New Study to Evaluate Tibulizumab in Systemic Sclerosis A randomized, double-blind, placebo-controlled study will assess the efficacy, safety, and tolerability of tibulizumab in adults with diffuse cutaneous SSc.

#SSWC2026: A randomized, double-blind, placebo-controlled study (TibuSURE, #NCT06843239) is looking to assess the efficacy, safety, and tolerability of #Tibulizumab in adults with diffuse cutaneous #SystemicSclerosis (SSc).

Learn more: https://bit.ly/4loDQFR

#RareDisease #SSc #TibuSURE